ASCO 2018 - Tarceva or Tarceva with Avastin as 1st Line for EGFR Positive NSCLC vs. Tagrisso or Vizimpro

Article and Video CATEGORIES

Cancer Journey

ABOUT

Howard Jack West, MD, Founder, Board President

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

ASCO 2018 - Tarceva or Tarceva with Avastin as 1st Line for EGFR Positive NSCLC vs. Tagrisso or Vizimpro

dbrock

Tue, 12/18/2018 - 14:38

ASCO 2018 Roundtable

Author

Howard (Jack) West, MD

Drs. H. Jack West, Medical Director - Thoracic Oncology Program at Swedish Cancer Institute, President and CEO of GRACE, Karen Kelly - Associate Director for Clinical Research at UC Davis Comprehensive Cancer Center, and Sandip Patel - Medical Oncologist and Associate Professor of Medicine at Moores Cancer Center, UC San Diego Health, gathered post meeting to discuss new information from ASCO 2018 regarding lung cancer.

In this roundtable video, the doctors discuss treatment with Tarceva or Tarceva with Avastin as first line therapy for EGFR Positive NSCLC vs. the use of Tagrisso or Vizimpro.

GRACE thanks the following sponsors for their support.

Video Language

English

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Article

The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.